Table 2.
Overall incidence of AEs and treatment-related AEs
| Adverse event | Any grade (n, %) | Grade ≥ 3 (n, %) |
|---|---|---|
| Any AE | 12 (100) | 11 (92) |
| Any treatment-related AE | 11 (92) | 9 (75) |
| Hematologic AE | ||
| Anemia | 9 (75) | 3 (25) |
| Leukopenia | 8 (67) | 1 (8) |
| Lymphopenia | 8 (67) | 2 (17) |
| Neutropenia | 7 (58) | 1 (8) |
| Thrombocytopenia | 5 (42) | 2 (17) |
| Lymphocytosis | 1 (8) | 0 |
| Nonhematologic AE | ||
| Increased creatinine | 4 (33) | 0 |
| Fatigue | 4 (33) | 0 |
| Dehydration | 2 (17) | 1 (8) |
| Weight loss | 2 (17) | 0 |
| Alkaline phosphatase increased | 2 (17) | 0 |
| Anorexia | 2 (17) | 1 (8) |
| ALT increased | 1 (8) | 0 |
| AST increased | 1 (8) | 0 |
| Constipation | 1 (8) | 0 |
| Diarrhea | 1 (8) | 0 |
| Dizziness | 1 (8) | 0 |
| Dyspnea | 1 (8) | 0 |
| Hiccups | 1 (8) | 0 |
| Hyperkalemia | 1 (8) | 0 |
| Hypocalcemia | 1 (8) | 0 |
| Hyponatremia | 1 (8) | 0 |
| Nasal congestion | 1 (8) | 0 |
| Nausea | 1 (8) | 0 |
| Sinus tachycardia | 1 (8) | 0 |
AEadverseevent,ASTaspartateaminotransferase,ALTalanineaminotransferase